{
  "docId": "019de077-5130-7668-92cb-6c77396e6bd2",
  "docSlug": "e021a2de9332664c5094197b4bc248cd",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 157 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 78,
  "pageCount": 132,
  "prevPage": 77,
  "nextPage": 79,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 3,
  "notes": "The slide provides a structured overview of three specific clinical trials (Balanced-HF, MIRACLE, MIRO-CKD).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-5130-7668-92cb-6c77396e6bd2/78",
  "deckHref": "/decks/019de077-5130-7668-92cb-6c77396e6bd2",
  "deckJsonHref": "/decks/019de077-5130-7668-92cb-6c77396e6bd2.json",
  "deckAnchorHref": "/decks/019de077-5130-7668-92cb-6c77396e6bd2#slide-78",
  "components": [
    {
      "bbox": {
        "h": 1,
        "w": 0.22,
        "x": 0.78,
        "y": 0
      },
      "kind": "other",
      "text": "Approved medicines, Late-stage development, Early development, Oncology, CVRM, R&I, Other, V&I, Rare Disease",
      "attrs": null,
      "subkind": "unclassified",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c064f72b-2f21-4953-9cd3-d346bcb01784",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.75,
        "x": 0.03,
        "y": 0.00185
      },
      "kind": "table",
      "text": "Trial, Population, Patients, Design, Endpoints, Status table for Balanced-HF, MIRACLE, and MIRO-CKD trials.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8a645c0a-a6f9-4575-b854-eb31887faba5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.75,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "balcinrenone/dapagliflozin (MR modulator + SGLT2 inhibitor) Heart failure, CKD",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8f50a1f9-327e-4307-8014-1eb9f7f06450",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 120,
      "from": 6,
      "beatId": "0c127c3c-ea10-450c-b057-64b7f7a0f03c",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Detailed overview of AstraZeneca's pipeline and portfolio",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}